Narrative Review of Controversies Involving Vasopressin Use in Septic Shock and Practical Considerations.

Conclusion: Vasopressin should remain second-line adjunct to norepinephrine to augment mean arterial pressures. Dosing should be initiated at 0.03 U/min, and higher doses offer minimal benefit. There are conflicting data on the impact of weight on vasopressin response. Studies have failed to show renal benefit with vasopressin use or an interaction with corticosteroid therapy. PMID: 31958982 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31958982?dopt=Abstract

Source: The Annals of Pharmacotherapy - January 19, 2020 Category: Drugs & Pharmacology Authors: Der-Nigoghossian C, Hammond DA, Ammar MA Tags: Ann Pharmacother Source Type: research

More News: Corticosteroid Therapy | Drugs & Pharmacology | Obesity | Septic Shock | Study